id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2011-D-0611-0089,FDA,FDA-2011-D-0611,Final Guidance Questions and Answers on Biosimilar Development and the BPCI Act Guidance for Industry,Other,Guidance,2021-09-20T04:00:00Z,2021,9,2021-09-20T04:00:00Z,,2021-09-20T15:02:28Z,,0,0,0900006484d94970
FDA-2011-D-0611-0088,FDA,FDA-2011-D-0611,"Questions and Answers on BiosimilarDevelopment and the Biologics Price
Competition and Innovation Act of 2009; Guidance for Industry;
Availability",Notice,Notice of Availability,2021-09-20T04:00:00Z,2021,9,2021-09-20T04:00:00Z,,2021-09-21T00:59:26Z,2021-20255,0,0,0900006484d93980